ParalysisBlinkER System for Facial Nerve Palsy Eyelid Closure

Study start date: October 1, 2025

Inclusion Criteria: 22 years of age or older * Unilateral facial palsy due to any of the following: Bell's palsy, Ramsay Hunt syndrome, malignant or benign tumor resection, Lyme disease, cerebrovascular accident (hemorrhagic or ischemic), or trauma * A deficit in eye closure during blinking, defined as a mean blink score ≤2.0 in the study eye on the scale by Mäkelä, et al, as graded by the investigator. * Willing and able to comply with the study procedures and follow-up * Willing and able to provide informed consent * English, Spanish, or Hebrew, Arabic -speaking * In a trial with the BlinkER System, the device produces blinks sufficient to cover the pupil in the study eye, defined as a mean grade ≥ 3.0 on the Mäkelä scale, as graded by the investigator. * Participant successfully completes BlinkER System training and certification Exclusion Criteria: * Bilateral facial paralysis (for example Parkinson's Disease) * History of prior intervention that is providing closure of the eyelids (e.g., facial reanimation, complete tarsorrhaphy surgery, etc.) * Has an implanted eyelid weight in the study eyelid. * History of diabetic neuropathy, unstable cardiovascular disease, neurologic disease causing severe cognitive or motor impairment, severe immunological deficiency, or malignant diseases that are not in remission * Signs of corneal infection, severe ocular surface inflammation, or significant periorbital skin inflammation/infection * Suspected or diagnosed epilepsy. * Cancerous lesions in the area where the BlinkER system electrodes will be applied. * Cardiac demand pacemaker, implanted defibrillator or other implanted electronic device * Cornea or iris abnormalities that preclude visualization of the pupil * Cranial nerve V palsy or neurotrophic keratitis * Synkinesis that results in eyelid closure * Known allergy to any of the patient-contacting materials of the BlinkeER electrode (i.e. polyethylene (PET) film tape or hydrogel) * Participants who are pregnant or nursing. * Participation in another ophthalmic clinical trial within one year prior to enrollment. Participant must also be willing to refrain from another ophthalmic study for the duration of the study. * Co-existing condition, either ocular or non-ocular that, in the judgement of the investigator could affect the safety or effectiveness of treatment or the compliance of the participant to the protocol.